A post-marketing safety analysis showed that the real-world rate of hearing-related events linked with Tepezza treatment was comparable to that found in clinical trials, according to a press release.
The 19-month analysis included data from thousands of patients with thyroid eye disease treated with Tepezza (teprotumumab-trbw, Horizon Therapeutics) since the drug’s FDA approval in 2020.
According to the release, about 10% of all cases reported to the safety database have included a hearing-related event. The most frequent hearing event was hypoacusis, followed by tinnitus. There were no